Q32 Bio Inc. SEC filings QTTB
Q32 Bio Inc. has 588 filings in SEC EDGAR's recent list, going back to Jan 6, 2016. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 28, 2026 | — |
| EFFECT | Filing | Jul 13, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2025 | — |
| CORRESP | Letter to the SEC | Aug 26, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2025 | — |
| EFFECT | Filing | Apr 21, 2025 | — |
| CORRESP | Letter to the SEC | Apr 17, 2025 | — |
| EFFECT | Filing | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2025 | — |
| EFFECT | Filing | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2024 | — |
| POS EX | Filing | Mar 13, 2024 | — |
| 425 | Filing | Mar 11, 2024 | — |
| 425 | Filing | Feb 21, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 14, 2024 | — |
| EFFECT | Filing | Feb 14, 2024 | — |
| CORRESP | Letter to the SEC | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Feb 12, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2024 | — |
| CORRESP | Letter to the SEC | Jan 26, 2024 | — |
| 425 | Filing | Jan 26, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2024 | — |
| 425 | Filing | Jan 3, 2024 | — |
| 425 | Filing | Nov 16, 2023 | — |
| 425 | Filing | Nov 16, 2023 | — |
| 425 | Filing | Nov 16, 2023 | — |
| 425 | Filing | Nov 16, 2023 | — |
| 425 | Filing | Nov 16, 2023 | — |
| EFFECT | Filing | Mar 17, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2023 | — |
| SEC STAFF LETTER | Filing | Apr 19, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 22, 2021 | — |
| EFFECT | Filing | Mar 12, 2021 | — |
| POSASR | Filing | Mar 11, 2021 | — |
| CT ORDER | Filing | Feb 3, 2021 | — |
| EFFECT | Filing | Apr 9, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2019 | — |
| CORRESP | Letter to the SEC | Apr 8, 2019 | — |
| CT ORDER | Filing | Mar 30, 2018 | — |
| EFFECT | Filing | Mar 27, 2018 | — |
| CORRESP | Letter to the SEC | Mar 23, 2018 | — |
| CORRESP | Letter to the SEC | Mar 23, 2018 | — |
| CERT | Filing | Mar 22, 2018 | — |
| 8-A12B | Filing | Mar 19, 2018 | — |
| CORRESP | Letter to the SEC | Mar 14, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2018 | — |
| DRSLTR | Filing | Feb 23, 2018 | — |
| DRS/A | Filing | Feb 23, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2018 | — |
| DRSLTR | Filing | Jan 30, 2018 | — |
| DRS/A | Filing | Jan 30, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2018 | — |
| DRS | Filing | Dec 22, 2017 | — |
| D | Filing | Aug 10, 2017 | — |
| D/A | Filing | Feb 16, 2017 | — |
| D | Filing | Jan 6, 2016 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QTTB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661998
- Former names
- Q32 Bio Inc. (until Nov 4, 2026); Homology Medicines, Inc. (until Mar 22, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.